Vanguard Group Inc. Raises Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Vanguard Group Inc. lifted its stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 25.6% in the 3rd quarter, Holdings Channel reports. The firm owned 1,551,802 shares of the company’s stock after purchasing an additional 316,128 shares during the quarter. Vanguard Group Inc.’s holdings in Tarsus Pharmaceuticals were worth $27,576,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Royal Bank of Canada lifted its stake in shares of Tarsus Pharmaceuticals by 122.0% in the second quarter. Royal Bank of Canada now owns 2,817 shares of the company’s stock valued at $50,000 after purchasing an additional 1,548 shares during the period. Tower Research Capital LLC TRC increased its position in shares of Tarsus Pharmaceuticals by 310.1% in the third quarter. Tower Research Capital LLC TRC now owns 3,736 shares of the company’s stock worth $66,000 after acquiring an additional 2,825 shares in the last quarter. UBS Group AG increased its position in shares of Tarsus Pharmaceuticals by 37.0% in the first quarter. UBS Group AG now owns 4,226 shares of the company’s stock worth $71,000 after acquiring an additional 1,142 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Tarsus Pharmaceuticals by 65.1% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,306 shares of the company’s stock worth $94,000 after acquiring an additional 2,092 shares in the last quarter. Finally, Public Employees Retirement System of Ohio acquired a new stake in shares of Tarsus Pharmaceuticals in the third quarter worth $94,000. Institutional investors and hedge funds own 90.01% of the company’s stock.

Analysts Set New Price Targets

TARS has been the subject of several recent research reports. Oppenheimer reissued an “outperform” rating and issued a $59.00 price objective (up previously from $55.00) on shares of Tarsus Pharmaceuticals in a research report on Wednesday, February 28th. Jefferies Financial Group upped their target price on shares of Tarsus Pharmaceuticals from $30.00 to $44.00 and gave the company a “buy” rating in a research note on Wednesday, March 6th. HC Wainwright upped their target price on shares of Tarsus Pharmaceuticals from $50.00 to $57.00 and gave the company a “buy” rating in a research note on Wednesday, February 28th. Barclays upped their target price on shares of Tarsus Pharmaceuticals from $40.00 to $50.00 and gave the company an “overweight” rating in a research note on Wednesday, February 28th. Finally, Lifesci Capital restated an “outperform” rating on shares of Tarsus Pharmaceuticals in a research note on Tuesday, December 26th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $48.38.

Tarsus Pharmaceuticals Trading Down 5.5 %

NASDAQ TARS opened at $36.17 on Friday. Tarsus Pharmaceuticals, Inc. has a 12 month low of $11.33 and a 12 month high of $40.40. The company has a debt-to-equity ratio of 0.15, a current ratio of 6.93 and a quick ratio of 6.85. The company has a market capitalization of $1.24 billion, a price-to-earnings ratio of -7.80 and a beta of 1.05. The company’s fifty day moving average price is $33.44 and its two-hundred day moving average price is $23.73.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its quarterly earnings results on Tuesday, February 27th. The company reported ($1.31) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.37) by $0.06. The business had revenue of $13.08 million during the quarter, compared to the consensus estimate of $4.63 million. During the same quarter in the previous year, the business posted ($0.49) earnings per share. As a group, research analysts predict that Tarsus Pharmaceuticals, Inc. will post -4.59 earnings per share for the current fiscal year.

Insider Transactions at Tarsus Pharmaceuticals

In related news, General Counsel Bryan Wahl sold 4,436 shares of the stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $30.60, for a total value of $135,741.60. Following the sale, the general counsel now owns 40,951 shares of the company’s stock, valued at approximately $1,253,100.60. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other Tarsus Pharmaceuticals news, COO Seshadri Neervannan sold 4,879 shares of the firm’s stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $30.60, for a total transaction of $149,297.40. Following the transaction, the chief operating officer now owns 64,767 shares of the company’s stock, valued at approximately $1,981,870.20. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, General Counsel Bryan Wahl sold 4,436 shares of the firm’s stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $30.60, for a total transaction of $135,741.60. Following the transaction, the general counsel now directly owns 40,951 shares in the company, valued at approximately $1,253,100.60. The disclosure for this sale can be found here. In the last three months, insiders have sold 24,496 shares of company stock worth $749,578. 11.54% of the stock is currently owned by insiders.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.